Insider buying · SEC Form 4

Insider Buying — Jun 8, 2026

Company insiders — CEOs, CFOs, directors and 10% owners — buying their own company's stock on the open market: every purchase of $250K or more from the previous day's Form 4 filings, largest first, with an AI summary of the day.

7insider buys
$36.4Mbought in total
5companies
4by CEOs, CFOs and other chiefs
HOODlargest: $15.1M

Every qualifying buy, largest first

StockInsiderValueSharesAvg priceTypeFiled
HOODRobinhood Markets Inc.Meyer MalkaDirector (via Ribbit-affiliated funds)$15.1M181,000$83.45AddedJun 5, 2026
Wtd avg $83.45; now $82.47 (−1.2%). Ribbit Capital fund vehicles; Malka disclaims beneficial ownership beyond pecuniary interest. Part of ongoing accumulation: also bought 249K shares at $80.39 on May 28. Stake now ~3.5M shares. Buying while HOOD executives are net sellers.
TXOTXO Partners, L.P.Bob R. SimpsonDirector / 10% Owner$8.23M600,000$13.72AddedJun 5, 2026
June 2: 230,847 units at $13.41 avg; June 3: 369,153 units at $13.91 avg. Wtd avg $13.72; now $13.44 (−2.0%). Stake raised to 16.2% of outstanding. Personal-funds buying campaign since May 21 totals ~$14.4M. 13D/A also filed. Energy-focused MLP.
NSPInsperity, Inc.Paul J. SarvadiChairman / CEO$7.93M233,000$34.05AddedJun 5, 2026
Transaction June 3 at $34.05 wtd avg (range $33.51–$34.45); now $35.38 (+3.9%). Stock surged 4.9% on the disclosure. Repeat buyer: also bought 100K shares in May. Post-purchase direct holdings: 699,670 shares + 1.1M indirect via Our Ship LP. HR/PEO sector.
SMMTSummit Therapeutics Inc.Robert W. DugganCo-CEO / Director$1.46M100,000$14.60AddedJun 8, 2026
Transaction June 4 at $14.60 (Nasdaq −4% day); now $14.77 (+1.2%). Indirect purchase via associated trust. Part of tri-insider cluster buy: Duggan + Zanganeh (co-CEO) + Soni (COO-CFO) all bought same day. Awaiting FDA review date for ivonescimab.
SMMTSummit Therapeutics Inc.Mahkam ZanganehCo-CEO / Director$1.46M100,000$14.60AddedJun 8, 2026
Transaction June 4 at $14.60 (Nasdaq −4% day); now $14.77 (+1.2%). Mahkam Zanganeh Revocable Trust; post-purchase trust holds 25.8M shares. Cluster buy alongside Duggan and Soni on the same day. June 2 company 8-K had authorized affiliate purchases under ATM program.
LODEComstock Inc.Pei Steven Yu-TsungDirector (via Gratia Capital)$1.45M360,000$4.03AddedJun 5, 2026
Three tranches June 1–3: 26,177 + 153,823 + 180,000 shares at avg ~$4.03 (range $3.93–$4.14); now $3.93 (−2.5%). Gratia Capital entity stake now ~1.89M shares. CEO DeGasperis also bought 10,682 shares separately (below threshold). Mining/energy materials company.
SMMTSummit Therapeutics Inc.Manmeet Singh SoniCOO / CFO / Director$722K50,000$14.45AddedJun 8, 2026
Transaction June 4: 25,000 shares at $14.43 + 25,000 shares at $14.46; now $14.77 (+2.3%). Post-purchase direct holdings: 3,123,603 shares. Third SMMT insider buying on June 4 alongside both co-CEOs into the market selloff.

AIThe day in insider buying

SEC Form 4 Insider Scan — June 8, 2026

Scanned EDGAR Form 4 filings filed June 5–8, 2026 (covering transactions June 1–4). 7 qualifying buys (≥ $250K, transaction type P) totalling $36.4M.

Market note: The Nasdaq fell ~4% on June 4 — its worst single-day loss since April 2025. Multiple insiders stepped in as buyers that day, most visibly at Summit Therapeutics.


Headline Filings

  • HOOD — Meyer Malka / Ribbit fund (Director) bought 181,000 shares ≈ $15.1M at $83.45 avg; now $82.47 (−1.2% since buy). (filing) Continuing multi-week accumulation (also bought 249K shares at $80.39 on May 28); Ribbit stake climbs to ~3.5M shares while HOOD executives sell.
  • TXO — Bob R. Simpson (Director / 10% Owner) bought 600,000 units ≈ $8.2M across June 2–3 at wtd avg $13.72; now $13.44 (−2.0%). (filing) Stake lifted to 16.2% of outstanding units. Part of an ongoing personal-funds campaign totalling ~$14.4M since May 21.
  • NSP — Paul J. Sarvadi (CEO / Chairman) bought 233,000 shares ≈ $7.9M on June 3 at $34.05 avg; now $35.38 (+3.9%). (filing) Stock jumped 4.9% on the announcement. Second large purchase in two months (also bought 100K shares in May). Post-purchase holdings: ~699K direct + 1.1M via partnership.
  • SMMT — Robert W. Duggan (Co-CEO) bought 100,000 shares ≈ $1.46M on June 4 at $14.60; now $14.77 (+1.2%). (filing) Part of a tri-insider cluster buy the same day.
  • SMMT — Mahkam Zanganeh (Co-CEO) bought 100,000 shares ≈ $1.46M on June 4 at $14.60 via revocable trust; now $14.77 (+1.2%). (filing) Trust post-purchase holdings: 25.8M shares.
  • LODE — Pei Steven Yu-Tsung / Gratia Capital (Director) bought 360,000 shares ≈ $1.45M across June 1–3 at avg ~$4.03; now $3.93 (−2.5%). (filing) Entity stake rises to ~1.89M shares. CEO DeGasperis also purchased separately on June 3 (10,682 shares, below $250K threshold).
  • SMMT — Manmeet Singh Soni (COO-CFO / Director) bought 50,000 shares ≈ $722K on June 4 at $14.44 avg; now $14.77 (+2.3%). (filing) All three SMMT insiders bought on the same day into the market selloff.

Notes

Theme 1 — SMMT cluster conviction buy into the selloff. Three Summit Therapeutics insiders (both co-CEOs + COO-CFO) each executed open-market purchases on June 4, the day the Nasdaq dropped ~4%. Combined value: ~$3.64M. All three are now slightly in-the-green (+1.2–2.3%). The June 2 company 8-K authorized insider/affiliate purchases under its ATM program, but these appear to be direct open-market transactions at prevailing prices. Catalyst to watch: FDA review date for ivonescimab (VEGF/PD-1 bispecific).

Theme 2 — Repeat/conviction CEO buying: NSP and TXO. Insperity's Sarvadi and TXO's Simpson are both repeat buyers deploying personal funds in size, suggesting strong conviction in their companies' near-term prospects. Sarvadi's combined May–June buys now total ~$11.1M personal capital; Simpson's YTD buying at TXO exceeds $14M.

Theme 3 — Contrarian fintech accumulation: HOOD. Meyer Malka's Ribbit-affiliated funds have now purchased ~430,000 HOOD shares in two weeks ($35M+) while insiders and executives have been net sellers. Classic "director buying while insiders sell" divergence worth monitoring.

Sector breakdown: Biotech/Pharma (SMMT), Financial Services (NSP, HOOD), Energy/MLP (TXO), Mining/Materials (LODE).

Most-bought stocks, last 30 days

  • RSG $201M · 2 buys, 2 insidersRepublic Services, Inc.
  • WGS $125M · 5 buys, 2 insidersGeneDx Holdings Corp.
  • ALKT $65.9M · 2 buys, 2 insidersAlkami Technology, Inc.
  • HOOD $65.3M · 4 buysRobinhood Markets Inc.
  • FBIN $31.3M · 4 buysFortune Brands Innovations, Inc.
  • NCLH $27.5M · 2 buys, 2 insidersNorwegian Cruise Line Holdings Ltd.
  • BH $26.9M · 2 buys, 2 insidersBiglari Holdings Inc.
  • TXO $21.6M · 4 buysTXO Partners, L.P.
  • FOUR $15.9M · 1 buyShift4 Payments, Inc.
  • NSP $15.9M · 2 buysInsperity, Inc.
  • PAR $10.5M · 1 buyPAR Technology Corp.
  • WCN $7.61M · 1 buyWaste Connections, Inc.
  • SRAD $7.52M · 3 buys, 2 insidersSportradar Group AG
  • MNSO $6.90M · 1 buyMINISO Group Holding Limited
  • NOMD $6.63M · 1 buyNomad Foods Limited
  • ONON $6.59M · 3 buys, 3 insidersOn Holding AG
  • MRP $6.42M · 1 buyMillrose Properties, Inc.
  • UPST $6.37M · 2 buys, 2 insidersUpstart Holdings, Inc.
  • TKO $6.00M · 3 buys, 2 insidersTKO Group Holdings, Inc.
  • UA $5.87M · 1 buyUnder Armour, Inc.

All scans

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.